Vivosim Labs Inc 's Cash & cash equivalent grew by 412.81 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Vivosim Labs Inc 's Quick Ratio to 3.19, Quick Ratio remained below Vivosim Labs Inc average.

Within Biotechnology & Pharmaceuticals industry 127 other companies have achieved higher Quick Ratio than Vivosim Labs Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1579 to 2517.

Explain Quick Ratio?
How much Cash & cash equivalents VIVS�s has?
What are VIVS�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/VIVS/financial-strength

https://api.csimarket.com/api/v1/companies/VIVS/fundamentals

https://api.csimarket.com/api/v1/companies/VIVS/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

VIVS Quick Ratio	(Sep 30 2026) Q2	(Jun 30 2026) Q1	(Mar 31 2026) Q4	(Dec 31 2025) Q3	(Sep 30 2025) Q2
Y / Y Current Liabilities Change	9.51 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	28.26 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	3.19	Subscribe	Subscribe	Subscribe	Subscribe
VIVS's Total Ranking	# 2517	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	41.68 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	412.81 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 128
Healthcare Sector	# 718
Overall Market	# 2517

Quick Ratio Statistics
High	Average	Low
51.82	12.6	0.67
(Dec 31 2021)		(Dec 31 2012)

Financial Statements
Vivosim Labs Inc 's Current Liabilities	$ 3 Millions	Visit VIVS's Balance sheet
Vivosim Labs Inc 's Cash & cash equivalent	$ 9 Millions	Visit VIVS's Balance sheet
Source of VIVS's Sales		Visit VIVS's Sales by Geography

Cumulative Vivosim Labs Inc 's Quick Ratio

VIVS's Quick Ratio for the trailling 12 Months

VIVS Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-12.69 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-31.9 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.99	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4404	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	2.43 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	10.69 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to VIVS Financial Strength Comparisons >> Go to Compare VIVS Quick Ratio to its Competitors

On the trailing twelve months basis VIVS Cash & cash equivalent grew by 28.26 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Vivosim Labs Inc 's Quick Ratio to 1.99, Quick Ratio remained below VIVS average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 156 other companies have achieved higher Quick Ratio than Vivosim Labs Inc . While Quick Ratio overall ranking has improved so far to 4404, from total ranking during the twelve months ending first quarter 2026 at 4469.

Explain Quick Ratio?
How much Cash & cash equivalents VIVS�s has?
What are VIVS�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 157
Healthcare Sector	# 976
Within the Market	# 4404

trailing twelve months Quick Ratio Statistics
High	Average	Low
35.41	11.73	1.31
(Dec 31 2021)		(Jun 30 2013)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Candel Therapeutics Inc	7.42	$ 203.116 Millions	$ 27.388 Millions
Inhibrx Biosciences Inc	7.31	$ 199.469 Millions	$ 27.302 Millions
4d Molecular Therapeutics Inc	7.16	$ 375.033 Millions	$ 52.394 Millions
Immunovant Inc	6.94	$ 722.274 Millions	$ 104.022 Millions
Repligen Corp	6.87	$ 862.979 Millions	$ 125.686 Millions
Kyverna Therapeutics Inc	6.79	$ 170.572 Millions	$ 25.136 Millions
Compass Therapeutics Inc	6.69	$ 163.058 Millions	$ 24.368 Millions
Black Diamond Therapeutics Inc	6.62	$ 102.030 Millions	$ 15.405 Millions
Krystal Biotech Inc	6.45	$ 916.484 Millions	$ 142.144 Millions
Voyager Therapeutics Inc	6.35	$ 106.806 Millions	$ 16.813 Millions
Cabaletta Bio Inc	6.33	$ 299.383 Millions	$ 47.332 Millions
Cognition Therapeutics inc	6.00	$ 30.758 Millions	$ 5.128 Millions
Replimune Group Inc	5.57	$ 307.833 Millions	$ 55.271 Millions
Denali Therapeutics Inc	5.42	$ 516.196 Millions	$ 95.258 Millions
In8bio Inc	5.32	$ 13.973 Millions	$ 2.628 Millions
Scholar Rock Holding Corp	5.16	$ 413.599 Millions	$ 80.124 Millions
Revolution Medicines Inc	4.81	$ 3,651.385 Millions	$ 758.773 Millions
Prokidney Corp	4.72	$ 141.864 Millions	$ 30.038 Millions
Caribou Biosciences Inc	4.71	$ 94.881 Millions	$ 20.144 Millions
Recursion Pharmaceuticals Inc	4.47	$ 549.853 Millions	$ 122.918 Millions
Lineage Cell Therapeutics Inc	4.42	$ 45.199 Millions	$ 10.217 Millions
Ginkgo Bioworks Holdings Inc	4.33	$ 285.361 Millions	$ 65.849 Millions
Fate Therapeutics Inc	4.26	$ 139.132 Millions	$ 32.691 Millions
Kymera Therapeutics Inc	4.16	$ 373.374 Millions	$ 89.723 Millions
Monte Rosa Therapeutics Inc	4.16	$ 577.726 Millions	$ 139.022 Millions
Vir Biotechnology Inc	4.08	$ 454.635 Millions	$ 111.332 Millions
Moderna Inc	3.93	$ 7,976.000 Millions	$ 2,028.000 Millions
Immunocore Holdings Plc	3.93	$ 901.298 Millions	$ 229.619 Millions
Alector Inc	3.92	$ 138.697 Millions	$ 35.415 Millions
Quince Therapeutics Inc	3.90	$ 39.821 Millions	$ 10.223 Millions

Date modified: 2026-11-13T21:37:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.